These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
823 related articles for article (PubMed ID: 28783719)
1. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Yao Z; Yaeger R; Rodrik-Outmezguine VS; Tao A; Torres NM; Chang MT; Drosten M; Zhao H; Cecchi F; Hembrough T; Michels J; Baumert H; Miles L; Campbell NM; de Stanchina E; Solit DB; Barbacid M; Taylor BS; Rosen N Nature; 2017 Aug; 548(7666):234-238. PubMed ID: 28783719 [TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705 [TBL] [Abstract][Full Text] [Related]
3. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612 [TBL] [Abstract][Full Text] [Related]
4. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576 [TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
6. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704 [TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307 [TBL] [Abstract][Full Text] [Related]
8. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Ming Z; Lim SY; Kefford RF; Rizos H Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489 [TBL] [Abstract][Full Text] [Related]
10. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344 [TBL] [Abstract][Full Text] [Related]
11. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724 [TBL] [Abstract][Full Text] [Related]
12. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
13. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800 [TBL] [Abstract][Full Text] [Related]
14. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459 [TBL] [Abstract][Full Text] [Related]
15. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238 [TBL] [Abstract][Full Text] [Related]
17. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830 [TBL] [Abstract][Full Text] [Related]